Please assess the completion status of the following clinical trial:

Trial Title: Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's signed informed consent obtained prior to any study-related procedure;~2. Adult men and women at least 18 years of age with end-stage renal disease who are recipients (or will be recipients) of a kidney transplant from a living or deceased donor;~3. No known contraindications to the administration of tacrolimus, other macrolides and study drugs excipients;~4. Patients must agree to use a highly reliable method of birth control;~5. Donor-recipient negative cross match test, and compatible AB0 blood type;~6. Able to swallow tablets and capsules~Exclusion Criteria:~1. Recipient of any transplanted organ other than kidney;~2. Recipient of a previous renal transplant;~3. Recipient of a kidney from a donor after cardiac death;~4. Recipient of a kidney from an AB0 incompatible or positive cross-match donor;~5. Current (not older than 3 months) anti-HLA Panel Reactive Antibody (PRA) levels higher than 30%. Whenever PRA, either complement-dependent cytotoxicity-PRA or calculated PRA , is not available, patients who are positive on solid-phase screening assay for anti-HLA antibodies must not be enrolled;~6. Recipient of a kidney with a cold ischemia time of ≥ 30 hours;~7. White blood cells count ≤ 2.8x109 cells/L unless ANC \>1.0x109/L;~8. Platelet count \< 50 x109 cells/L;~9. ALT or AST levels \>3 times the normal upper limit during the 30 days prior transplant procedure;~10. Current abuse of drugs or alcohol;~11. Incapable of understanding purpose and risk of study, unable to give written informed consent or unwilling to comply with study protocol;~12. Treatment with any other investigational agent in the 30 days prior to enrolment;~13. Kidney recipients and/or donors positive for HCV (HCV-RNA positive or HCV-Ab positive respectively);~14. Kidney recipients and/or donors positive for HBV (HBV-DNA or HBS-Ag positive);~15. Recipients positive for HIV;~16. Patient or donor with current diagnosis or history of malignancy within the past 5 years except basal or non-metastatic squamous cell carcinoma of the skin successfully treated;~17. Uncontrolled concomitant infection, systemic infection requiring treatment or any other unstable condition that could interfere with study objectives;~18. Severe diarrhoea, vomiting, active peptic ulcer or GI disorder that may affect absorption of tacrolimus;~19. Known hypersensitivity to tacrolimus other macrolides and study drugs excipients;~20. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use reliable methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Envarsus® (tacrolimus) (Type: EXPERIMENTAL): prolonged-release tablets once daily and orally
- Prograf or Advagraf (Type: ACTIVE_COMPARATOR): Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).